<!DOCTYPE html>
<html><head>
		<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
		<title>Zotero Report</title>
		<link rel="stylesheet" type="text/css" href="index_files/detail.css">
		<link rel="stylesheet" type="text/css" media="screen,projection" href="index_files/detail_screen.css">
		<link rel="stylesheet" type="text/css" media="print" href="index_files/detail_print.css">
	</head>
	<body>
		<ul class="report combineChildItems">
			<li id="item_GGF7WGW7" class="item journalArticle">
			<h2>Are high pharmaceutical prices morally justifiable?</h2>
				<table>
					<tbody><tr>
						<th>Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Alexander Ren</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="http://search.ebscohost.com/login.aspx?direct=true&amp;AuthType=cookie,ip,cpid&amp;custid=s6264891&amp;db=aqh&amp;AN=133535143&amp;site=ehost-live&amp;scope=site">http://search.ebscohost.com/login.aspx?direct=true&amp;AuthType=cookie,ip,cpid&amp;custid=s6264891&amp;db=aqh&amp;AN=133535143&amp;site=ehost-live&amp;scope=site</a></td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>1</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>23</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>Penn Bioethics Journal</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>21505462</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>Spring 2017</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Penn Bioethics Journal</td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>3/13/2019, 8:32:59 AM</td>
					</tr>
					<tr>
					<th>Library Catalog</th>
						<td>EBSCOhost</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Several pharmaceutical companies have undergone intense 
criticism for selling drug products at exorbitant prices. Patent and 
market exclusivity laws allow these companies to engage in such extreme 
price gouging. If pharmaceutical companies are legally permitted to set 
high prices, the next question is whether said prices are morally 
justifiable. This problem can be addressed from multiple perspectives. 
This paper will begin with a discussion of the costs underlying drug 
development, move to the funding for drug research, and then explore 
more formal philosophical principles, namely the doctrine of justum 
pretium and Rawlsian distributive justice. Finally, I summarize some 
possible, commonly accepted solutions proposed by other authors. 
Ultimately, we will see that high pharmaceutical prices are not morally 
justifiable, for drug companies essentially prioritize profit over the 
public good.</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>3/13/2019, 8:32:59 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>3/13/2019, 8:32:59 AM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>PHARMACEUTICAL industryPHARMACEUTICAL research</li>
				</ul>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_X8UBU2PC">
<div><h2>Generics work just as well</h2>
<blockquote>
<p>Many prescription brands have <span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">generic versions</span></strong></span> that <span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">are much less expensive</span></strong></span>. <span style="text-decoration: underline;"><span style="border: none;">Some might believe that generic brands are inferior in quality</span></span>, and that this allows for lower prices. But this is not true. <span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">The
 Food and Drug Administration (FDA) assures consumers that “Generics 
have the same quality, safety, and strength as branded medicines”</span></strong></span> (Center for Drug Evaluation and Research 2003).</p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>generics</li>
				</ul>
					</li>
					<li id="item_6SDLADFU">
<div><h2>Immorality of high prices</h2>
<blockquote>
<p style="margin: 0in 0in 8pt; line-height: 107%; font-size: 11pt; font-family: Helvetica;"><span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">Healthcare constitutes one of the most basic human needs</span></strong></span>
 for citizens in our society, given its ability to allow us to access 
other freedoms through which we can ultimately find self-determination. <span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">High
 pharmaceutical prices essentially represent a form of price 
discrimination, since pharmaceutical companies are unequally 
distributing life-saving drugs on the basis of one’s socioeconomic 
standing.</span></strong></span> According to Rawls’s interpretation of &nbsp;the theory of distributive justice, <span style="text-decoration: underline;"><strong>this violates the natural rights of citizens in a just society and can be condemned as immoral</strong></span>.</p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>discrimination</li>
					<li>inequality</li>
					<li>morality</li>
				</ul>
					</li>
				</ul>
				<h3 class="attachments">Attachments</h3>
				<ul class="attachments">
					<li id="item_2ICFQL3K">EBSCO Full Text					</li>
				</ul>
			</li>


			<li id="item_LGZINRX2" class="item webpage">
			<h2>Expanding the Use of Generic Drugs</h2>
				<table>
					<tbody><tr>
						<th>Type</th>
						<td>Web Page</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://aspe.hhs.gov/basic-report/expanding-use-generic-drugs">https://aspe.hhs.gov/basic-report/expanding-use-generic-drugs</a></td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2015-06-13T04:13:16-04:00</td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>3/14/2019, 8:16:16 AM</td>
					</tr>
					<tr>
					<th>Language</th>
						<td>en</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>ASPE ISSUE BRIEF Expanding the Use of Generic Drugs By: ASPE Staff December 1, 2010</td>
					</tr>
					<tr>
					<th>Website Title</th>
						<td>ASPE</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>3/14/2019, 8:16:16 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>3/14/2019, 8:16:16 AM</td>
					</tr>
				</tbody></table>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_JZWCNAWH">
<div><h2>Generic adoption decreases brand-name prices</h2>
<blockquote>
<p style="margin: 0in 0in 8pt; line-height: 107%; font-size: 11pt; font-family: Helvetica;"><span style="font-size: 7pt; line-height: 107%;">Another
 possible pathway for savings is a reduction in average branded prices 
paid by consumers resulting from generic substitution. A study by Rizzo 
and Zeckhauser found that </span><span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">a higher share of generic prescriptions result in lower average brand drug prices</span></strong></span><span style="font-size: 7pt; line-height: 107%;">. The theory is that </span><span style="text-decoration: underline;"><strong>consumers
 are more likely to substitute generics for higher cost branded drugs 
and conversely less likely to substitute generics for lower cost branded
 drugs</strong></span><span style="font-size: 7pt; line-height: 107%;">. This </span><span style="text-decoration: underline;"><strong><span style="background: yellow none repeat scroll 0% 0%;">selective
 substitution would then effectively lower the average cost of branded 
drugs by leading brand name manufacturers to choose lower initial 
prices. This study found that a 10 percent increase in the generic 
substitution rate is associated with a 15.6 percent decline in the 
average price paid for branded drugs</span></strong></span><span style="font-size: 7pt; line-height: 107%;">(10).</span></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>generics</li>
					<li>solutions</li>
				</ul>
					</li>
				</ul>
				<h3 class="attachments">Attachments</h3>
				<ul class="attachments">
					<li id="item_2LP2RS8U">ib.pdf					</li>
					<li id="item_9Z7DNQHD">Snapshot					</li>
				</ul>
			</li>


			<li id="item_2GRF9KPN" class="item journalArticle">
			<h2>Generic script share and the price of brand-name drugs: the role of consumer choice</h2>
				<table>
					<tbody><tr>
						<th>Type</th>
						<td>Journal Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>John A. Rizzo</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Richard Zeckhauser</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://doi.org/10.1007/s10754-008-9052-0">https://doi.org/10.1007/s10754-008-9052-0</a></td>
					</tr>
					<tr>
					<th>Volume</th>
						<td>9</td>
					</tr>
					<tr>
					<th>Issue</th>
						<td>3</td>
					</tr>
					<tr>
					<th>Pages</th>
						<td>291-316</td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>International Journal of Health Care Finance and Economics</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>1573-6962</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>2009-09-01</td>
					</tr>
					<tr>
					<th>Journal Abbr</th>
						<td>Int J Health Care Finance Econ</td>
					</tr>
					<tr>
					<th>DOI</th>
						<td><a href="http://doi.org/10.1007/s10754-008-9052-0">10.1007/s10754-008-9052-0</a></td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>3/14/2019, 8:19:30 AM</td>
					</tr>
					<tr>
					<th>Library Catalog</th>
						<td>Springer Link</td>
					</tr>
					<tr>
					<th>Language</th>
						<td>en</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Pharmaceutical expenditures have grown rapidly in recent 
decades, and now total nearly 10% of health care costs. Generic drug 
utilization has risen substantially alongside, from 19% of scripts in 
1984 to 47% in 2001, thus tempering expenditure growth through 
significant direct dollar savings. However, generic drugs may lead to 
indirect savings as well if their use reduces the average price of those
 brand-name drugs that are still purchased. Prior work indicates that 
brand-name producers do not lower their prices in the face of generic 
competition, and our study confirms that finding. However, prior work is
 silent on how the mix of consumer choices between generic and 
brand-name drugs might affect the average price of those brand-name 
drugs that are purchased. We use a nationally representative panel of 
data on drug utilization and costs for the years 1996–2001 to examine 
how the share of an individual’s prescriptions filled by generics 
(generic script share) affects his average out-of-pocket cost for 
brand-name drugs, and the net cost paid by the insurer. Our principal 
finding is that a higher generic script share lowers average brand-name 
prices to consumers, presumably because consumers are more likely to 
substitute generics when brand-name drugs would cost them more. This 
effect is substantial: a 10% increase in the consumer’s generic script 
share is associated with a 15.6% decline in the average price paid for 
brand-name drugs by consumers. This implies that the potential cost 
savings to consumers from generic substitution are far greater than 
prior work suggests. In contrast, the percentage reduction in average 
brand costs to health plans is far smaller, and statistically 
insignificant.</td>
					</tr>
					<tr>
					<th>Short Title</th>
						<td>Generic script share and the price of brand-name drugs</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>3/14/2019, 8:19:30 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>3/14/2019, 8:19:30 AM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>Brands and generics</li>
					<li>Consumer choice</li>
					<li>D40</li>
					<li>Drug prices</li>
					<li>I11</li>
				</ul>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_T5P9QXK2">
<div><h2>Consumer bias toward brand name drugs is larger for more serious conditions</h2>
<blockquote>
<p>To begin, insurers almost always offer the consumer a lower copay for
 generic drugs, which favors generics. However, consumers will also 
consider the quality of the drug, which may be a counterbalancing 
advantage for brand-name drugs. Drug quality has two components: (1) the
 drug’s safety and effectiveness for its purpose, and (2) the importance
 of its purpose. Relating to (1), leaving price aside, we would assume 
that consumers are more likely to buy brand-name drugs if they assume 
that brand-name drugs are substantially safer or more effective than 
generic drugs. This might advantage well-known brands, or drugs that are
 known to be high-tech developments. Component (2) would suggest that <em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;">a consumer would be more likely to use a brand-name drug than a generic for a life-threatening condition than for a skin rash</em>. Indeed, <em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="background: yellow none repeat scroll 0% 0%;">survey
 evidence indicates that consumers perceive quality differentials 
between brand-name drugs and generic substitutes to be greater when the 
drugs are used to treat more serious conditions</span></em>.28</p>
</blockquote></div>
					</li>
				</ul>
				<h3 class="attachments">Attachments</h3>
				<ul class="attachments">
					<li id="item_2MBVUXDD">rizzo2009.pdf					</li>
				</ul>
			</li>


			<li id="item_KTXZAATX" class="item webpage">
			<h2>Health Insurance Coverage in the United States: 2016</h2>
				<table>
					<tbody><tr>
						<th>Type</th>
						<td>Web Page</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.census.gov/library/publications/2017/demo/p60-260.html">https://www.census.gov/library/publications/2017/demo/p60-260.html</a></td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>3/14/2019, 8:38:38 AM</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>3/14/2019, 8:38:38 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>3/14/2019, 8:38:38 AM</td>
					</tr>
				</tbody></table>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_65WEY2CL">
<div><h2>91.2% of Americans are insured</h2>
<p>The Census Bureau writes in 2017 that 91.2 percent of Americans had health insurance in 2016.</p>
<blockquote>
<p>The uninsured rate decreased between 2015 and 2016 by 0.3 percentage 
points as measured by the CPS ASEC. In 2016, the per­centage of people 
without health insurance coverage for the entire calendar year was 8.8 
percent, or 28.1 million, lower than the rate and number of uninsured in
 2015 (9.1 percent or 29.0 million). <span style="text-decoration: underline; background-color: #ffff00;"><strong>The percentage of people with health insurance coverage for all or part of 2016 was 91.2 percent</strong></span>, higher than the rate in 2015 (90.9 percent).</p>
</blockquote></div>
					</li>
				</ul>
				<h3 class="attachments">Attachments</h3>
				<ul class="attachments">
					<li id="item_667MWMAA">Health Insurance Coverage in the United States: 2016					</li>
				</ul>
			</li>


			<li id="item_KD4E6I6C" class="item newspaperArticle">
			<h2>The Cost of Not Taking Your Medicine</h2>
				<table>
					<tbody><tr>
						<th>Type</th>
						<td>Newspaper Article</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Jane E. Brody</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.nytimes.com/2017/04/17/well/the-cost-of-not-taking-your-medicine.html">https://www.nytimes.com/2017/04/17/well/the-cost-of-not-taking-your-medicine.html</a></td>
					</tr>
					<tr>
					<th>Publication</th>
						<td>The New York Times</td>
					</tr>
					<tr>
					<th>ISSN</th>
						<td>0362-4331</td>
					</tr>
					<tr>
					<th>Date</th>
						<td>April 17, 2017</td>
					</tr>
					<tr>
					<th>Section</th>
						<td>Well</td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>3/11/2019, 7:00:00 PM</td>
					</tr>
					<tr>
					<th>Library Catalog</th>
						<td>NYTimes.com</td>
					</tr>
					<tr>
					<th>Language</th>
						<td>en-US</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>Nonadherence to prescriptions causes some 125,000 deaths a year in the United States alone.</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>3/12/2019, 11:00:22 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>3/13/2019, 8:20:42 AM</td>
					</tr>
				</tbody></table>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>adherence</li>
					<li>Asthma</li>
					<li>Drugs (Pharmaceuticals)</li>
					<li>Heart</li>
					<li>Statins (Cholesterol-Lowering Drugs)</li>
					<li>Transplants</li>
				</ul>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_FR3ASUTA">
<div><h2>Lack of adherence - $50 threshold</h2>
<blockquote>
<p><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;">“When the co-pay for a drug hits $50 or more, adherence really drops,</em>”
 Dr. Bender said. Or when a drug is very expensive, like the biologics 
used to treat rheumatoid arthritis that cost $4,000 a month, patients 
are less likely to take them or they take less than the prescribed 
dosage, which renders them less effective.</p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>adherence</li>
				</ul>
					</li>
					<li id="item_JKKYVEQD">
<div><h2>Lack of adherence - costs</h2>
<blockquote>
<p><span style="font-size: 11pt; line-height: 107%; font-family: Helvetica;">“<em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;">Studies
 have consistently shown that 20 percent to 30 percent of medication 
prescriptions are never filled, and that approximately 50 percent of 
medications for chronic disease are not taken as prescribed</em>,” 
according to a review in Annals of Internal Medicine. People who do take
 prescription medications — whether it’s for a simple infection or a 
life-threatening condition — typically take only about half the 
prescribed doses. <em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;">This </em><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="background: yellow none repeat scroll 0% 0%;">lack of adherence,</span></em> the Annals authors wrote, <em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="background: yellow none repeat scroll 0% 0%;">is estimated to cause approximately 125,000 deaths and at least 10 percent of hospitalizations</span></em>, <span class="gmail-StyleUnderline" style="font-weight: normal; text-decoration: underline;">and to cost the American health care systembetween $100 billion and $289 billion a year</span>.</span></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>adherence</li>
				</ul>
					</li>
					<li id="item_3KEVTKUN">
<div><h2>Lack of adherence - frequency</h2>
<blockquote>
<p>Studies have shown that <em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="background: yellow none repeat scroll 0% 0%;">a
 third of kidney transplant patients don’t take their anti-rejection 
medications, 41 percent of heart attack patients don’t take their blood 
pressure medications</span></em>, and half of children with asthma either don’t use their inhalers at all or use them inconsistently.</p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>adherence</li>
				</ul>
					</li>
				</ul>
			</li>


			<li id="item_BJGQDNJV" class="item webpage">
			<h2>The EpiPen pricing-surge scandal brings out the worst parts of our government and healthcare system</h2>
				<table>
					<tbody><tr>
						<th>Type</th>
						<td>Web Page</td>
					</tr>
					<tr>
						<th class="author">Author</th>
						<td>Brett LoGiurato</td>
					</tr>
					<tr>
					<th>URL</th>
						<td><a href="https://www.businessinsider.com/epipen-cost-increase-healthcare-insurance-2016-8">https://www.businessinsider.com/epipen-cost-increase-healthcare-insurance-2016-8</a></td>
					</tr>
					<tr>
					<th>Date</th>
						<td>Aug. 27, 2016</td>
					</tr>
					<tr>
					<th>Accessed</th>
						<td>3/11/2019, 7:00:00 PM</td>
					</tr>
					<tr>
					<th>Abstract</th>
						<td>The EpiPen price increase exposes some of the worst parts of 
the US political and healthcare systems and explains many of the faults 
with both.</td>
					</tr>
					<tr>
					<th>Website Title</th>
						<td>Business Insider</td>
					</tr>
					<tr>
					<th>Date Added</th>
						<td>3/12/2019, 11:00:10 AM</td>
					</tr>
					<tr>
					<th>Modified</th>
						<td>3/12/2019, 11:00:10 AM</td>
					</tr>
				</tbody></table>
				<h3 class="notes">Notes:</h3>
				<ul class="notes">
					<li id="item_YFHYDSVC">
<div><h2>2x epi-pens, 2x profits</h2>
<blockquote>
<p><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="font-size: 11pt; line-height: 107%; background: yellow none repeat scroll 0% 0%;">In
 2010, a change in federal guidelines made it possible for Mylan to sell
 twice as many EpiPens with each device. That change recommended that 
two EpiPens be included in each package</span></em><span style="font-size: 7pt; line-height: 107%; font-family: Helvetica;"> — hence, the familiar two pack. Doctors have never made me question the better-safe-than-sorry nature of the new guidelines. </span><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="font-size: 11pt; line-height: 107%;">They say if you can't get to a hospital within 30 minutes of your first injection, you should probably inject the other one</span></em><span style="font-size: 7pt; line-height: 107%; font-family: Helvetica;">. </span><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="font-size: 11pt; line-height: 107%; background: yellow none repeat scroll 0% 0%;">That,
 and other changes provided a significant financial benefit to Mylan. At
 the time, about 35% of prescriptions were for a single injector, but 
Mylan scrapped that packaging in favor of the dual injectors.</span></em></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>epi-pen</li>
					<li>Mylan</li>
					<li>price hike</li>
				</ul>
					</li>
					<li id="item_F3VG9EUG">
<div><h2>Epinephrine is cheap</h2>
<blockquote>
<p><strong><span style="font-size: 11pt; font-family: 'Helvetica Neue'; color: #000000; background-color: #ffff00; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">Epinephrine, the actual medicine in EpiPens, is</span></strong><span style="font-size: 6.999999999999999pt; font-family: 'Helvetica Neue'; color: #000000; background-color: transparent; font-weight: 400; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> cheap. According to public-health nonprofit Management Sciences for Health, epinephrine's 2014 price in some parts of the developing world was </span><strong><span style="font-size: 11pt; font-family: 'Helvetica Neue'; color: #000000; background-color: #ffff00; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">less than $1 a milliliter</span></strong><span style="font-size: 6.999999999999999pt; font-family: 'Helvetica Neue'; color: #000000; background-color: transparent; font-weight: 400; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. </span><strong><span style="font-size: 11pt; font-family: 'Helvetica Neue'; color: #000000; background-color: #ffff00; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">One EpiPen auto-injector from Mylan contains about one-third of a milliliter</span></strong><span style="font-size: 6.999999999999999pt; font-family: 'Helvetica Neue'; color: #000000; background-color: transparent; font-weight: 400; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. </span><strong><span style="font-size: 11pt; font-family: 'Helvetica Neue'; color: #000000; background-color: #ffff00; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">When Mylan acquired the auto injectors as part of a 2007 deal, they were priced at about $57</span></strong><span style="font-size: 6.999999999999999pt; font-family: 'Helvetica Neue'; color: #000000; background-color: transparent; font-weight: 400; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">, according to Truven Health Analytics. </span><strong><span style="font-size: 11pt; font-family: 'Helvetica Neue'; color: #000000; background-color: #ffff00; font-variant: normal; text-decoration: underline; -webkit-text-decoration-skip: none; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">Today, the list price for a two-pack is $608</span></strong><span style="font-size: 6.999999999999999pt; font-family: 'Helvetica Neue'; color: #000000; background-color: transparent; font-weight: 400; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. </span></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>Mylan</li>
					<li>profit</li>
				</ul>
					</li>
					<li id="item_KRD2LKRP">
<div><h2>Importance of epinephrine</h2>
<blockquote>
<p><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="font-size: 11pt; line-height: 107%; background: yellow none repeat scroll 0% 0%;">Epinephrine
 is a must-have, life-saving medication for thousands of people. Because
 it is quick to expire, those people need to purchase it every year, no 
matter the price, or risk their lives.</span></em></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>epi-pen</li>
					<li>generics</li>
					<li>Mylan</li>
				</ul>
					</li>
					<li id="item_C6TD4YVR">
<div><h2>Mylan's monopoly</h2>
<blockquote>
<p><span style="font-size: 7pt; line-height: 107%; font-family: Helvetica;">Options for bringing down the price are limited. </span><em style="font-family: Helvetica; font-weight: bold; font-style: normal; text-decoration: underline;"><span style="font-size: 11pt; line-height: 107%; background: yellow none repeat scroll 0% 0%;">Mylan has a stranglehold on the EpiPen market that isn't going anywhere</span></em><span class="gmail-StyleUnderline" style="font-weight: normal; text-decoration: underline;"><span style="font-size: 11pt; line-height: 107%; font-family: Helvetica;">
 — the barriers to enter the market are enormous. Further, the company 
can raise the price of the life-saving medication again and again 
without any rejection, because it's allowed to. The government has set 
up incentives for the life-saving medication to be everywhere, yet has 
made no effort to control its cost.</span></span></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>epi-pen</li>
					<li>monopoly</li>
					<li>Mylan</li>
				</ul>
					</li>
					<li id="item_KVYT5UMX">
<div><h2>Old tech, new price</h2>
<blockquote>
<p><span class="gmail-StyleUnderline" style="font-weight: normal;"><span style="font-size: 11pt; line-height: 107%; font-family: Helvetica;"><span style="font-size: 11pt; line-height: 107%; font-family: Helvetica;"><span style="text-decoration: underline;"><strong><span style="background-color: #ffff00;">The EpiPen is nothing new — it is a decades-old device.</span></strong></span> But when <span style="text-decoration: underline; background-color: #ffff00;"><strong>Mylan</strong></span> acquired the product, it saw an opportunity. It began marketing to concerned parents of children with allergies</span><span style="font-size: 7.0pt; line-height: 107%; font-family: Helvetica;">— my mother, a rightful worrier, among them — </span><span style="font-size: 11.0pt; line-height: 107%; font-family: Helvetica;">and <span style="text-decoration: underline; background-color: #ffff00;"><strong>turned less than $1 worth of medicine into a billion-dollar business</strong></span></span></span></span><span class="gmail-StyleUnderline" style="font-weight: normal;"><span style="font-size: 11pt; line-height: 107%; font-family: Helvetica;"><span style="font-size: 7.0pt; line-height: 107%; font-family: Helvetica;">.</span></span></span></p>
</blockquote></div>
				<h3 class="tags">Tags:</h3>
				<ul class="tags">
					<li>epi-pen</li>
					<li>monopoly</li>
					<li>Mylan</li>
				</ul>
					</li>
				</ul>
			</li>

		</ul>
	
</body></html>